<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20789">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836249</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-320-0110 (China)</org_study_id>
    <secondary_id>2013-000636-10</secondary_id>
    <nct_id>NCT02836249</nct_id>
  </id_info>
  <brief_title>Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the efficacy, safety, and tolerability of
      tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive
      and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic
      hepatitis B virus (HBV) infection in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study GS-US-320-0110 is an international study planned to enroll participants in global
      countries, including China. However, due to the review timeline difference in China, full
      enrollment was reached in the main study (NCT01940471) before China was able to participate.
      Therefore, this registration only includes the China cohorts as they will not be part of the
      main study analysis. Data for China cohorts will be analyzed separately at a later time.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 19, 2015</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Actual">December 15, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with hepatitis B virus (HBV) DNA &lt; 29 IU/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>The primary efficacy endpoint is determined by the achievement of HBV DNA &lt; 29 IU/mL at Week 48.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with hepatitis B e antigen (HBeAg) loss with seroconversion to antibody against HBeAb (anti-HBe) at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in hip bone mineral density (BMD) at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in spine BMD at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 48 in serum creatinine</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>HBV</condition>
  <condition>Chronic HBV Infections</condition>
  <arm_group>
    <arm_group_label>TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAF + TDF placebo for 144 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TDF + TAF placebo for 144 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAF</intervention_name>
    <description>TAF 25 mg tablet administered orally once daily</description>
    <arm_group_label>TAF</arm_group_label>
    <arm_group_label>Open-label TAF</arm_group_label>
    <other_name>GS-7340</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF</intervention_name>
    <description>TDF 300 mg tablet administered orally once daily</description>
    <arm_group_label>TDF</arm_group_label>
    <other_name>Viread®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAF Placebo</intervention_name>
    <description>TAF placebo tablet administered orally once daily</description>
    <arm_group_label>TDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF Placebo</intervention_name>
    <description>TDF placebo tablet administered orally once daily</description>
    <arm_group_label>TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Ability to understand and sign a written informed consent form, which must be
             obtained prior to initiation of study procedures

          -  Adult males and non-pregnant, non-lactating females

          -  Documented evidence of chronic HBV infection

          -  HBeAg-positive, chronic hepatitis B with all of the following:

               -  HBeAg-positive at screening

               -  Screening HBV DNA ≥ 2 x 10^4 IU/mL

               -  Screening serum alanine aminotransferase (ALT) level &gt; 60 U/L (males) or &gt; 38
                  U/L (females) and ≤ 10 x the upper limit of the normal range (ULN)

          -  Treatment-naive participants (defined as &lt; 12 weeks of oral antiviral treatment with
             any nucleoside or nucleotide analogue) OR treatment-experienced participants (defined
             as participants meeting all entry criteria [including HBV DNA and serum ALT criteria]
             and with ≥ 12 weeks of previous treatment with any nucleoside or nucleotide analogue)

          -  Previous treatment with interferon (pegylated or non-pegylated) must have ended at
             least 6 months prior to the baseline visit

          -  Adequate renal function

          -  Normal ECG

        Key Exclusion Criteria:

          -  Females who are breastfeeding

          -  Males and females of reproductive potential who are unwilling to use an &quot;effective&quot;,
             protocol specified method(s) of contraception during the study

          -  Co-infection with hepatitis C virus, HIV, or hepatitis D virus

          -  Evidence of hepatocellular carcinoma

          -  Any history of, or current evidence of, clinical hepatic decompensation

          -  Abnormal hematological and biochemical parameters, including aspartate
             aminotransferase (AST) &gt; 10 x ULN

          -  Received solid organ or bone marrow transplant

          -  History of malignancy within the past 5 years, with the exception of specific cancers
             that are cured by surgical resection; individuals under evaluation for possible
             malignancy are not eligible

          -  Currently receiving therapy with immunomodulators (eg, corticosteroids),
             investigational agents, nephrotoxic agents, or agents capable of modifying renal
             excretion

          -  Individuals receiving ongoing therapy with drugs not to be used with tenofovir
             alafenamide or tenofovir disoproxil fumarate or individuals with a known
             hypersensitivity to study drugs, metabolites, or formulation excipients

          -  Current alcohol or substance abuse judged by the investigator to potentially
             interfere with participant compliance

          -  Any other clinical condition or prior therapy that, in the opinion of the
             Investigator, would make the participant unsuitable for the study or unable to comply
             with dosing requirements

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Ditan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PLA 302 Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xianya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Eighth People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Medical University, Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No. 3 Hospital, Zhongshan Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guiyang Medical College</name>
      <address>
        <city>Guiyang</city>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Hainan Province</name>
      <address>
        <city>Hainan</city>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Hunan</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Hospital of Nanjing City</name>
      <address>
        <city>Jiangsu</city>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province People's Hospital</name>
      <address>
        <city>Jiangsu</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Jiangxi</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Hospital Jilin University</name>
      <address>
        <city>Jilin</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan Infectious Disease Hospital</name>
      <address>
        <city>Jinan</city>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Liaoning</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, JiaoTong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>85 Hospital of People's Liberation Army</name>
      <address>
        <city>Shanghai</city>
        <zip>200235</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <zip>110006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3rd Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Sichuan</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Affiliated Hospital Kunming Medical College</name>
      <address>
        <city>Yunnan</city>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 2, 2017</lastchanged_date>
  <firstreceived_date>July 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Viread</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
